Cargando…

Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial

INTRODUCTION: For patients with rheumatoid arthritis (RA) whose treatment with a tumour necrosis factor inhibitor (TNFi) is failing, several biological treatment options are available. Often, another TNFi or a biological with another mode of action is prescribed. The objective of this study was to c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Manders, Sofie HM, Kievit, Wietske, Adang, Eddy, Brus, Herman L, Moens, Hein J Bernelot, Hartkamp, Andre, Hendriks, Lidy, Brouwer, Elisabeth, Visser, Henk, Vonkeman, Harald E, Hendrikx, Jos, Jansen, Tim L, Westhovens, Rene, van de Laar, Mart AFJ, van Riel, Piet LCM
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4489004/ https://www.ncbi.nlm.nih.gov/pubmed/25997746 http://dx.doi.org/10.1186/s13075-015-0630-5

Ejemplares similares

TNFi Cycling Versus Changing Mechanism of Action in TNFi‐Experienced Patients: Result of the Corrona CERTAIN Comparative Effectiveness Study
por: Curtis, Jeffrey R., et al.
Publicado: (2021)

Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry
por: Harrold, Leslie R., et al.
Publicado: (2016)

Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics
por: Frisell, Thomas, et al.
Publicado: (2018)

Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry
por: Vermeer, Marloes, et al.
Publicado: (2013)

Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry
por: Mease, Philip J, et al.
Publicado: (2019)

Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort
por: Vermeer, Marloes, et al.
Publicado: (2012)

Baseline Anti-Citrullinated Protein Antibody Status and Response to Abatacept or Non-TNFi Biologic/Targeted-Synthetic DMARDs: US Observational Study of Patients with RA
por: Harrold, Leslie R., et al.
Publicado: (2021)

Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic
por: Druce, Katie L, et al.
Publicado: (2017)

Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
por: Silva-Fernández, Lucía, et al.
Publicado: (2018)

How age and sex affect the erythrocyte sedimentation rate and C-reactive protein in early rheumatoid arthritis
por: Siemons, Liseth, et al.
Publicado: (2014)

Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices
por: Bansback, Nick, et al.
Publicado: (2020)

The relationship between change in subjective outcome and change in disease: a potential paradox
por: Kievit, Wietske, et al.
Publicado: (2010)

Persistence of low disease activity after tumour necrosis factor inhibitor (TNFi) discontinuation in patients with psoriatic arthritis
por: Huynh, D H, et al.
Publicado: (2017)

Case report: JAKi and TNFi dual therapy is a potential treatment strategy for difficult-to-treat rheumatoid arthritis
por: Chen, Jing-Wen, et al.
Publicado: (2022)

Systematic review of patient-reported outcome measures (PROMs) for assessing disease activity in rheumatoid arthritis
por: Hendrikx, Jos, et al.
Publicado: (2016)

Interaction of TNFi and conventional synthetic DMARD in SARS-CoV-2 vaccine response in axial spondyloarthritis and psoriatic arthritis
por: G.S. Saad, Carla, et al.
Publicado: (2023)

Tapering and discontinuation of methotrexate in patients with RA treated with TNF inhibitors: data from the DREAM registry
por: Manders, Sofie H M, et al.
Publicado: (2015)

Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: a retrospective claims analysis
por: Grabner, Michael, et al.
Publicado: (2017)

TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD
por: Regierer, Anne Constanze, et al.
Publicado: (2021)

Maintained activity in ankylosing spondylitis patients treated with TNFi and/or NSAID for at least 12 weeks: a cross-sectional study in Brazil
por: de Toledo, Ricardo Acayaba, et al.
Publicado: (2022)

Commentary on Cohen et al.: Role of Clinical Factors in Precision Medicine Test to Predict Nonresponse to TNFi Therapies in Rheumatoid Arthritis
por: Cohen, Stanley, et al.
Publicado: (2022)

Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA
por: Jani, Meghna, et al.
Publicado: (2017)

Structural Lesion Progression of the Sacroiliac Joint and Clinical Features in axSpA During TNFi Reduction: A Retrospective Cohort Study
por: Mo, Qian, et al.
Publicado: (2021)

Correction: Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA
Publicado: (2017)

Cardiovascular case fatality in rheumatoid arthritis is decreasing; first prospective analysis of a current low disease activity rheumatoid arthritis cohort and review of the literature
por: Meek, Inger L, et al.
Publicado: (2014)

Hyperuricaemia: a marker of increased cardiovascular risk in rheumatic patients: analysis of the ACT-CVD cohort
por: Meek, Inger L, et al.
Publicado: (2014)

Relationship of pain and fatigue with health-related quality of life and work in patients with psoriatic arthritis on TNFi: results of a multi-national real-world study
por: Conaghan, P G, et al.
Publicado: (2020)

IL-10 Induced by mTNF Crosslinking-Mediated Reverse Signaling in a Whole Blood Assay Is Predictive of Response to TNFi Therapy in Rheumatoid Arthritis
por: Krasselt, Marco, et al.
Publicado: (2022)

Determinants of Engagement in Face-to-Face and Online Patient Support Groups
por: Van Uden-Kraan, Cornelia F, et al.
Publicado: (2011)

Association between TNFi anti-drug antibodies, smoking, and disease activity in patients with inflammatory arthritis: Results from a Norwegian cross-sectional observational study
por: Michelsen, Brigitte, et al.
Publicado: (2022)

Non-Steroidal Anti-Inflammatory Drugs: An Overview of Cardiovascular Risks
por: Meek, Inger L., et al.
Publicado: (2010)

A genetic risk score composed of rheumatoid arthritis risk alleles, HLA-DRB1 haplotypes, and response to TNFi therapy – results from a Swedish cohort study
por: Jiang, Xia, et al.
Publicado: (2016)

Patient participation in decisions about disease modifying anti-rheumatic drugs: a cross-sectional survey
por: Nota, Ingrid, et al.
Publicado: (2014)

Abatacept (CTLA4Ig) treatment increases the remission rate in rheumatoid arthritis patients refractory to methotrexate treatment
por: Westhovens, R, et al.
Publicado: (2004)

Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials
por: Helliwell, Philip S, et al.
Publicado: (2020)

Evaluation of long-term TNFi effectiveness after a first switch in early axial spondyloarthritis considering time-varying prescription bias: an inverse-probability weighting analysis of the DESIR cohort
por: Pons, Marion, et al.
Publicado: (2022)

Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease Registries and Claims Databases
por: Salinas, Claudia A., et al.
Publicado: (2022)

Working mechanism of a multidimensional computerized adaptive test for fatigue in rheumatoid arthritis
por: Nikolaus, Stephanie, et al.
Publicado: (2015)

Acceptance of New Technology: A Usability Test of a Computerized Adaptive Test for Fatigue in Rheumatoid Arthritis
por: Nikolaus, Stephanie, et al.
Publicado: (2014)

Proton-pump inhibitors are associated with a reduced risk for bleeding and perforated gastroduodenal ulcers attributable to non-steroidal anti-inflammatory drugs: a nested case-control study
por: Vonkeman, Harald E, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_u7lu0roerv6mouvfgfb7cqp3o0